本文選題：阿托伐他汀　切入點(diǎn)：高血壓　出處：《中國老年學(xué)雜志》2017年19期 　論文類型：期刊論文

【摘要】：目的探討阿托伐他汀對高血壓患者血管內(nèi)皮細(xì)胞損傷修復(fù)及PERK、IRE1α、Bi P、Ero1-Lα蛋白表達(dá)的影響。方法 88例高血壓患者通過隨機(jī)數(shù)表法分為研究線和對照組各44例。對照組采用高血壓基礎(chǔ)干預(yù)措施,研究組在對照組干預(yù)基礎(chǔ)上加用阿托伐他汀,兩組均持續(xù)治療2個(gè)月。對比兩組臨床療效,分析治療前后兩組內(nèi)質(zhì)網(wǎng)應(yīng)激(ER stress)標(biāo)記蛋白(Ero1-Lα、Bi P、IRE1α、PERK)、血管內(nèi)皮功能指標(biāo)[內(nèi)皮素(ET)、一氧化氮(NO)、肱動(dòng)脈血流介導(dǎo)血管擴(kuò)張率(FMD)]、血清炎癥因子[白細(xì)胞介素(IL)-6、腫瘤壞死因子(TNF)-α、高敏C反應(yīng)蛋白(hs-CRP)]水平變化。結(jié)果研究組總有效率高于對照組(P0.05);治療前兩組Ero1-Lα、Bi P、IRE1α、PERK光密度值對比無明顯差異(P0.05),治療后兩組各指標(biāo)水平較治療前降低,且研究組均低于對照組(均P0.05);治療前兩組ET、NO、FMD水平比較無明顯差異(P0.05),治療后兩組各指標(biāo)水平較治療前改善,且研究組ET水平低于對照組,NO、FMD水平高于對照組(P0.05);治療前研究組IL-6、TNF-α、hs-CRP水平與對照組比較無明顯差異(P0.05),治療后兩組炎癥因子水平均降低,且研究組均低于對照組(P0.05)。結(jié)論采用阿托伐他汀治療高血壓患者可有效降低PERK、IRE1α、Bi P、Ero1-Lα蛋白及血清炎癥因子表達(dá)水平,促使血管內(nèi)皮細(xì)胞損傷修復(fù),提高治療效果。
[Abstract]:Objective to investigate the effects of Atto vastatin on the repair of vascular endothelial cell injury and the expression of PERKN IRE1 偽 Bi PERO1-L 偽 protein in hypertensive patients. Methods 88 patients with hypertension were divided into two groups by random number method: 44 cases in the study line and 44 cases in the control group. Basic interventions with hypertension, The study group was treated with Atto vastatin on the basis of the intervention of the control group, and the two groups were treated continuously for 2 months. Endoplasmic reticulum stress (ER / S) marker protein Ero1-L 偽 (Bi PnIRE1 偽), vascular endothelial function (et), nitric oxide (no), brachial artery blood flow mediated vasodilation (FMDR), serum inflammatory factor (IL-6) and tumor necrosis were analyzed before and after treatment. Results the total effective rate in the study group was higher than that in the control group (P 0.05), and there was no significant difference in the optical density of the two groups before and after treatment (P 0.05). There was no significant difference in FMD level between the two groups before and after treatment (P 0.05), and the levels of each index in the two groups were improved after the treatment compared with the control group (P 0.05), and there was no significant difference in FMD between the two groups before and after treatment. The level of et in the study group was lower than that in the control group, and the level of FMD in the study group was higher than that in the control group (P 0.05), and the level of IL-6 TNF- 偽 hs-CRP in the study group was not significantly different from that in the control group before treatment. Conclusion the treatment with Atto vastatin can effectively reduce the expression of PERKE IRE1 偽 and serum inflammatory factors, promote the repair of vascular endothelial cell injury and improve the therapeutic effect.
【作者單位】： 上海市浦東新區(qū)公利醫(yī)院心血管內(nèi)科;
【基金】：上海市浦東新區(qū)衛(wèi)生系統(tǒng)學(xué)科帶頭人附帶課題(No.PWRd2015-11)
【分類號】：R544.1
，

本文編號：1594819